Abstract: The present disclosure relates to a biomarker for metastatic bladder cancer. According to the present disclosure, it was confirmed that bladder cancer cell lines increase in infiltration and migration capacity while acquiring anti-cancer drug resistance, and it was confirmed that the expression of ATP8B1, CCND1, CDH12, FERMT1, HSPD1, HSPE1, ID3, MAML3, CDKNI A, ELF4, MCM3, AREG, BMP6, CAV1, CAV2, COL8A2, CTSK, EBI3, EREG, GSN, ITGA2B, JAK3, L1CAM, LAMA3, LAMC2, LCN2, OLFML2A, PDGFC, PRKCG, SSCSD, THBS3, VASN, MMP3, SERPINB2, VCAN, ZP3, ACTA2, CACNA2D1, FAS, PDGFRB, SH3PXD2A, TAGLN, ACP2, CTSD, MMP11, TPP1, CD44, ESM1, FOXD1, HEG1, TCF4, VEGFC, ABL1, APOLD1, BDNF, DZIP1, LEF1, MYC, NAV1, NRP2, PKDCC, TMCC3, and CDA is increased in bladder cancer cells with increased infiltration and metastasis. In addition, it was confirmed that selected genes are associated with metastasis and prognosis of cancer in bladder cancer patients.

Abstract: The present invention relates to a novel biomarker for diagnosing cancer, and a use thereof. STC1, a novel biomarker for diagnosing or predicting the prognosis of cancer according to the present invention, was found to be related to poor prognosis of cancer patients according to the expression level, and was found to be overexpressed in various cancer cell lines. In addition, STC1 was found to be a biomarker related to the proliferation, invasion, and migration (metastasis) of cancer cells. In addition, it was found that STC1 is detected in the serum or urine of bladder cancer patients, and can be effectively used for diagnosing and predicting the prognosis of bladder cancer by identifying differences in expression according to the patient's clinical stage.